Free tool
FAERS Monitor: Xelpros
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206185 or its brand name (Xelpros, Latanoprost). Reports on generic versions are filed under their own applications.
Reports
34,052
Serious
15,454
45% of reports
Hospitalization
6,645
Death reported
1,861
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- treatment failure5,808
- drug ineffective2,307
- fatigue1,759
- eye irritation1,475
- off label use1,243
- headache1,241
- diarrhoea1,207
- eye pain1,100
- dizziness1,086
- death1,075
- nausea1,046
- dyspnoea1,045
- vision blurred994
- pain923
- asthenia866
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 104 |
| 2005 | 104 |
| 2006 | 82 |
| 2007 | 86 |
| 2008 | 111 |
| 2009 | 121 |
| 2010 | 132 |
| 2011 | 312 |
| 2012 | 617 |
| 2013 | 520 |
| 2014 | 707 |
| 2015 | 1,208 |
| 2016 | 1,676 |
| 2017 | 1,712 |
| 2018 | 2,149 |
| 2019 | 2,437 |
| 2020 | 8,333 |
| 2021 | 2,169 |
| 2022 | 2,165 |
| 2023 | 2,358 |
| 2024 | 2,310 |
| 2025 | 2,565 |
| 2026 | 2,074 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,020,107 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| treatment failureSignal | 5,808 | 46.5 | 45.4 | 241,320 |
| eye irritationSignal | 1,475 | 16.2 | 15.4 | 20,565 |
| eye painSignal | 1,100 | 12.3 | 11.6 | 11,175 |
| vision blurredSignal | 994 | 4.5 | 4.2 | 2,697 |
| asthenia | 866 | 1.4 | 1.3 | 110 |
| fatigue | 1,759 | 1.4 | 1.3 | 205 |
| dizziness | 1,086 | 1.3 | 1.3 | 98 |
| headache | 1,241 | 1.2 | 1.2 | 52 |
| diarrhoea | 1,207 | 1.2 | 1.1 | 26 |
| dyspnoea | 1,045 | 1.1 | 1.1 | 18 |
| drug ineffective | 2,307 | 1.1 | 1.0 | 15 |
| pain | 923 | 0.9 | 0.9 | 5 |
| off label use | 1,243 | 0.9 | 0.8 | 22 |
| nausea | 1,046 | 0.8 | 0.8 | 45 |
| death | 1,075 | 0.8 | 0.7 | 76 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.